CC-93269

· Celgene

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CC-93269, covering 2025-04-17 to 2025-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]

See pricing